Xeris Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xeris Biopharma Holdings, Inc. (XERS) on March 28, 2025. The report details significant changes to the Company's Board of Directors, including the resignation of one director, the retirement of another, and the appointment of a new director.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Resignation: Ms. Ricki Fairley resigned from the Board of Directors effective March 28, 2025. The resignation was not due to any disagreement with the Company.
- Retirement: Mr. John Schmid will not stand for reelection at the 2025 Annual Meeting. His term expires at that meeting. This decision was not due to any disagreement with the Company.
- Appointment: Mr. James Brady was appointed to the Board effective March 28, 2025, as a Class I director. He is expected to serve as Chair of the Audit Committee following the 2025 Annual Meeting.
Management Commentary and Compensation
Mr. Brady brings over thirty years of experience, including roles as Chief Financial Officer at MedImmune (AstraZeneca). He is eligible for compensation under the non-employee director program, which includes:
- An initial equity grant of 100,000 restricted stock units (RSUs) granted on March 28, 2025.
- Future annual equity grants of 50,000 RSUs commencing the year after the initial grant.
- Cash compensation as described in the Company's 2024 Definitive Proxy Statement.
The Board determined Mr. Brady qualifies as independent under Nasdaq listing standards. An indemnification agreement was executed to provide protection for his service.
Key Facts for Investor Verification
- Verify the exact vesting schedule for Mr. Brady's 100,000 initial RSUs (vesting in three equal annual installments).
- Confirm the date of the 2025 Annual Meeting to determine the expiration of Mr. Schmid's term and the start of Mr. Brady's Audit Committee Chair role.
- Review the Company's 2024 Definitive Proxy Statement for details on cash compensation for non-employee directors.
- Check subsequent filings to confirm if Mr. Brady is nominated for reelection at the 2025 Annual Meeting.